Ácido bempedoico. Mecanismo de acción y propiedades farmacocinéticas y farmacodinámicas
Authors:
Open Access
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Clínica e Investigación en Arteriosclerosis
- Vol. 33, 53-57
Abstract
No abstract availableKeywords
Funding Information
- Daiichi Sankyo Co Ltd
This publication has 13 references indexed in Scilit:
- Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trialJournal of Clinical Lipidology, 2019
- Lipid-Lowering AgentsCirculation Research, 2019
- Bempedoic Acid (ETC-1002): ATP Citrate Lyase InhibitorCardiology in Review, 2019
- Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled studyAtherosclerosis, 2018
- ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemiaCurrent Opinion in Lipidology, 2017
- Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosisNature Communications, 2016
- Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate LyaseCurrent Atherosclerosis Reports, 2016
- Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemiaJournal of Clinical Lipidology, 2015
- Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With HypercholesterolemiaJACC, 2013
- AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolismJournal of Lipid Research, 2013